Endocrine Immune-Related Adverse Events Are Independent Predictors of Survival in Patients with Lung Cancer

Endocrine Immune-Related Adverse Events Are Independent Predictors of Survival in Patients with Lung Cancer

Lung cancer (LC) is a serious health problem worldwide. Survival outcomes have improved over time due to the widespread use of novel therapeutic agents, including immune checkpoint inhibitors (ICIs). Endocrine immune-related adverse events (e-irAEs) are common in LC patients treated with ICIs. We pe...

Full description

Saved in:
Bibliographic Details
Published in:Cancers Vol. 16; no. 9; p. 1764
Main Authors: Panagiotou, Emmanouil, Ntouraki, Sofia, Vathiotis, Ioannis A, Livanou, Maria Effrosyni, Trimis, Athanasios, Evangelou, Georgios, Charpidou, Andriani, Syrigos, Konstantinos, Peppa, Melpomeni
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 01-05-2024
Subjects:
Cancer
Cancer patients
Cancer therapies
Care and treatment
Chemotherapy
Cytotoxicity
Development and progression
Diabetes
Diabetes mellitus
Disease
Hyperthyroidism
Hypothesis testing
Hypothyroidism
Immune checkpoint inhibitors
Immune system
Immunotherapy
Lung cancer
Lung cancer, Non-small cell
Medical prognosis
Metastasis
Multivariate analysis
Non-small cell lung carcinoma
Oncology, Experimental
Patient outcomes
Patients
Public health
Regression analysis
Statistical analysis
Survival
Thyroid gland
Thyroid hormones
Greece
endocrine toxicity
small-cell lung cancer
immune-related adverse events
thyroid disorders
PD-L1
CTLA-4
diabetes mellitus
immune checkpoint inhibitors
PD-1
pituitary disorders
non-small-cell lung cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer (LC) is a serious health problem worldwide. Survival outcomes have improved over time due to the widespread use of novel therapeutic agents, including immune checkpoint inhibitors (ICIs). Endocrine immune-related adverse events (e-irAEs) are common in LC patients treated with ICIs. We performed a retrospective study of patients with LC who received treatment with ICIs at a tertiary referral center between January 2014 and October 2023. In total, 983 LC patients were included in the study. E-irAEs presented at a median time of 4.1 months and included hypothyroidism (15.6%), hyperthyroidism (4.3%), adrenal insufficiency (0.4%), hypophysitis (0.4%), and diabetes mellitus (0.2%). These toxicities were not related to the duration of treatment or the type of ICIs. Most (97.6%) e-irAEs were mild (grade 1-2). Median overall survival (OS) was higher in LC patients who experienced e-irAEs (31.6 months) compared to those who did not (10.8 months). The difference remained statistically significant in the 3-month (HR: 0.42) and 6-month landmark analysis (HR: 0.51). The OS advantage was observed in both patients with NSCLC (HR: 0.36) and SCLC (HR: 0.27). Additional research is needed to validate the role of e-irAEs as an independent predictor of survival outcomes in patients with LC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16091764